Business Context and Reporting Period
Company: Arrowhead Research Corporation (formerly Arrowhead Pharmaceuticals, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2007
Business Model: A development-stage nanotechnology company utilizing a portfolio approach. It operates four majority-owned subsidiaries (Insert Therapeutics, Calando Pharmaceuticals, Unidym, and Aonex) to commercialize technologies in life sciences, electronics, and energy. The company also funds sponsored research at universities (e.g., Caltech, Stanford, Duke) to secure exclusive licensing rights.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2007 | Six Months Ended Mar 31, 2007 | Balance Sheet (Mar 31, 2007) |
|---|---|---|---|
| Revenue | $(3,697) | $7,394 | N/A |
| Operating Expenses | $8,432,841 | $12,917,574 | N/A |
| Net Loss | $(6,173,809) | $(9,880,979) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $21,591,701 |
| Total Assets | N/A | N/A | $26,904,512 |
| Total Liabilities | N/A | N/A | $2,427,717 |
| Stockholders' Equity | N/A | N/A | $24,476,795 |
| Debt | N/A | N/A | $0 (No long-term debt) |
Note: Revenue for the three-month period shows a negative value due to a reversal of a prior period grant billing. The company has no product sales revenue.
Material Changes vs. Prior Period
- Increased Losses: Net loss increased to $6.2 million for the quarter ended March 31, 2007, compared to $5.2 million in the same period in 2006. This is attributed to accelerated development activities and Phase I clinical trial preparations.
- Operating Expenses: Total operating expenses rose 41% year-over-year for the quarter.
- R&D Expenses: Increased 43% to $4.5 million, driven by outside lab/contract services (up 272%) and the write-off of goodwill to In-Process R&D ($963,000).
- Salaries: Increased 38% to $2.0 million due to new executive hires (e.g., CEO at Insert) and expanded technical staff.
- G&A Expenses: Increased 22% to $1.5 million, primarily due to legal fees for the Unidym/CNI merger and recruiting costs.
- Cash Position: Cash and cash equivalents decreased from $28.0 million (Sept 30, 2006) to $21.6 million (Mar 31, 2007), a reduction of approximately $6.4 million, primarily due to operating cash outflows of $11.7 million over the six-month period.
Outlook, Risks, and Management Commentary
- Subsidiary Progress:
- Insert Therapeutics: Phase I clinical trial for IT-101 (anti-cancer) is underway; data expected mid-2007. Sufficient cash to fund through Q2 Fiscal 2008.
- Calando Pharmaceuticals: Preparing to file an IND for CALAA-01 (RNAi therapeutic) in late 2007. Sufficient capital through Q2 Fiscal 2008 if milestones are met.
- Unidym: Merged with Carbon Nanotechnologies, Inc. (CNI) on April 20, 2007 (subsequent event). Arrowhead accelerated a $4 million capital commitment to Unidym in connection with this merger.
- Aonex: Seeking a partner for commercialization of LED wafer technology; currently in a phase-down mode.
- Liquidity: Management believes current cash ($21.6 million) is sufficient to fund operations through Fiscal 2007. The company has no debt and relies on equity financing.
- Capital Commitments: Arrowhead has the option to provide an additional $7 million to Calando and $4 million to Unidym based on milestone achievements. Failure to fund may result in forfeiture of equity interest.
- Risks:
- Development stage company with no product revenue; significant losses expected to continue.
- Uncertainty regarding clinical trial success, regulatory approval, and commercialization timelines.
- Dependence on future financing to fund operations and capital commitments.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $21.6 million cash balance against the $11.7 million operating cash burn over six months and upcoming capital commitments ($7M to Calando, $4M to Unidym).
- Clinical Milestones: Monitor the Phase I results for Insert's IT-101 and the IND filing status for Calando's CALAA-01, as these are critical for future funding and valuation.
- Unidym Merger Integration: Assess the impact of the April 2007 merger with CNI on Unidym's revenue potential and Arrowhead's diluted ownership (dropped to ~59.8% undiluted).
- Revenue Recognition: Note the lack of product revenue and the reliance on grants/development fees, which are currently negligible.
- Goodwill Write-offs: Review the $963,000 write-off of Calando goodwill to In-Process R&D and the prior write-off of Aonex goodwill, indicating conservative accounting but potential asset impairment risks.